FDA Issues Guidance On IDEs For Knee Cartilage Replacement
This article was originally published in The Gray Sheet
Executive Summary
Investigational device exemption (IDE) applications for knee cartilage replacement products should include a detailed product description, manufacturing and packaging methodology, and nonclinical testing data to assess biological responses and toxicology, FDA advises in a July 9 1draft guidance
You may also be interested in...
Regulatory News In Brief
The latest FDA guidances and other regulatory updates for device makers.
Pain And Function Are Best Endpoints For Knee Cartilage Trials – FDA Panel
Joint pain and function are the most clinically meaningful efficacy outcomes and should both be used as primary endpoints for clinical trials of cellular products for treatment of knee cartilage defects, FDA's Cellular, Tissue and Gene Therapies Advisory Committee recommends
Pain And Function Are Best Endpoints For Knee Cartilage Trials – FDA Panel
Joint pain and function are the most clinically meaningful efficacy outcomes and should both be used as primary endpoints for clinical trials of cellular products for treatment of knee cartilage defects, FDA's Cellular, Tissue and Gene Therapies Advisory Committee recommends